Rocket Pharmaceuticals (RCKT) Net Equity Issued and Repurchased (2015 - 2024)

Rocket Pharmaceuticals (RCKT) has 10 years of Net Equity Issued and Repurchased data on file, last reported at $118.7 million in Q4 2024.

• For the quarter ending Q4 2024, Net Equity Issued and Repurchased rose 169.16% year-over-year to $118.7 million; the trailing twelve-month figure through Dec 2024 stood at $182.5 million (up 959.85% YoY), and the FY2024 full-year result was $182.5 million, up 959.85% from the prior year.
• Net Equity Issued and Repurchased grew to $118.7 million in Q4 2024, from $63.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $171.7 million in Q3 2023 to a low of -$171.7 million in Q4 2023.
• A 5-year average of $25.6 million and a median of $17.2 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 485.94% in 2023, while the deepest fall reached 378.68% in 2023.
• Tracing RCKT's Net Equity Issued and Repurchased over 5 years: stood at -$874000.0 in 2020, then sank by 905.95% to -$8.8 million in 2021, then surged by 800.61% to $61.6 million in 2022, then slumped by 378.68% to -$171.7 million in 2023, then jumped by 169.16% to $118.7 million in 2024.
• Business Quant data shows RCKT's Net Equity Issued and Repurchased at $118.7 million in Q4 2024, $63.8 million in Q3 2024, and -$171.7 million in Q4 2023.